- Sanofi (SNY -0.1%) Q2 results (€M): Revenues: 8,868 (-4.3%); Operating Income: 1,436 (-25.9%); Net Income: 1,158 (-11.1%); Non-GAAP Net Income: 1,680 (-8.7%); EPS: €0.90 (-10.0%); Non-GAAP EPS: €1.31 (-7.1%); Quick Assets: 6,076 (-33.6%).
- Sales by Global Business Units: Sanofi Genzyme (Specialty Care): 1,245; Diabetes & Cardiovascular: 1,603; General Medicines & Emerging Markets: 4,498; Sanofi Pasteur (Vaccines): 797; Merial (Animal Health): 725.
- Key Product Sales: Lantus: 1,465; Lovenox: 414; Plavix: 392; Aubagio: 315; Renvela/Renagel: 208; Cerezyme: 199; Allegra: 39.
- 2016 Guidance: EPS: to be stable at CER; currency impact: -4%.